4 most recent filings and news items mentioning KROS. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/KROS/news?limit=20"
Pull KROS filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayKeros Therapeutics initiated a Phase 2 trial for rinvatercept in Duchenne muscular dystrophy and reported a Q2 net loss of $28.7 million, with cash expected to fund operations through mid-2028. The company reported a 48% decrease in operating costs due to restructuring.
View filing at SEC.gov →Nauticus Robotics entered an exchange agreement to swap existing secured term loans for Series C preferred stock. This debt-for-equity transaction aims to restructure the company's liabilities and simplify its capital structure.
View filing at SEC.gov →Keros Therapeutics announced the appointment of Anne Prener to its board of directors. This leadership change is expected to strengthen the company's clinical expertise as it continues advancing its therapy pipeline.
View filing at SEC.gov →Keros Therapeutics President and CEO Jasbir Seehra will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The presentation will be webcast live and archived for investor access.
View filing at SEC.gov →